A registration certificate for the injectable drug Tezspire (tezepelumab) has been granted to AstraZeneca by the Ministry of Health of Russia. It means that adults and children aged 12 and above suffering from severe bronchial asthma can now find solace in this treatment option. Amgen is the manufacturer of the drug in Russia.
Tezspire is a medicine used to treat adults and adolescents (12 years of age and older) with severe asthma. It is used as an additional treatment in adults and adolescents with severe asthma that is not adequately controlled by a combination of high-dose corticosteroids taken by inhalation plus another asthma medicine.
